Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is by far the most prevalent form of dementia in adults over 65 years old. Amyloid β peptide (Aβ)-containing senile plaques are one of the neuropathological hallmarks of AD. The gradual accumulation of aggregated Aβ peptide initiates a complex multistep cascade, which include gliosis, inflammatory changes, oxidative stress, tangle formation (microtubule changes), neuritic/synaptic changes, and transmitter loss that finally lead to dementia. One of the strategies used to increase the clearance of Aβ peptide from the brain involves immunization with Aβ peptide 1–42 (Aβ1–42). However, clinical trials of active immunization were halted when patients in the study developed meningocephalitis. We have recently reported that semi-allogeneic somatic cell hybrids generated by the fusion of EL-4 T lymphoma cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d) can protect C57BL/6 mice (H-2b) challenged with a tumorigenic dose of EL-4 cells. The results of our studies are entirely consistent with the concept that the semi-allogeneic vaccine (made of RAG X EL-4 cell hybrids) induce a potent T cell-mediated (Th-1) response, that instructs T lymphocytes to kill autologous (EL-4) tumor cells. We have subsequently modified RAG X EL-4 cell hybrids to specifically target Aβ1–42. Ten-week-old female C57BL/6 APP transgenic mice (APPswe, PSEN1dE9) were treated with a single dose of modified RAG X EL-4 somatic cell hybrids, injected intraperitoneally (i.p.). At six months of age, all mice were sacrificed and their brains were fixed and sectioned to count the amyloid plaques. We observed that the brains of APP mice, treated with a single dose of the semi-allogeneic cell hybrids formulated with Aβ1–42, showed less numerous and smaller plaques compared to the brains of APP mice treated with Aβ1–42 in PBS or with unmodified RAG X EL-4 cell hybrids in PBS. The results of these preliminary animal studies led us to hypothesize that a T cell-mediated (Th-1) immune response targeting the Aβ1–42 will help clear this peptide from the brain, resulting in enhanced cognition, without the risk of adverse events such as meningocephalitis.

Transmissible long-term neuroprotective and pro-cognitive effects of 1–42 beta-amyloid with A2T icelandic mutation in an Alzheimer's disease mouse model

Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy

Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study

Amyloid β induces interneuron-specific changes in the hippocampus of APPNL-F mice

Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease

Intracerebral inoculation of healthy non-transgenic rats with a single aliquot of oligomeric amyloid-β (1-42) profoundly and progressively alters brain function throughout life

Targeting high-affinity nicotinic receptors protects against the functional consequences of β-amyloid in mouse hippocampus

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.

Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice

Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice

Lentivirus-Mediated Expression of Human Secreted Amyloid Precursor Protein-Alpha Promotes Long-Term Induction of Neuroprotective Genes and Pathways in a Mouse Model of Alzheimer's Disease

Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer's Disease

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Repeated exposure to novelty promotes resilience against the amyloid-beta effect through dopaminergic stimulation

Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis